---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021538"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:20:10.886876+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q3 revenue $33.3M (+19% YoY); net income $1.3M vs loss

## Summary
- Revenue $33.3M (19% YoY); gross margin 66.1% vs 58.4%; net income $1.3M ($0.01 EPS) vs loss $5.0M (-$0.04 EPS).
- Adjusted EBITDA $4.5M vs loss $1.0M in prior year quarter; cash from operations $4.6M (vs $1.7M used).
- FY25 revenue guidance reiterated $131-135M (+11-15% YoY).
- Pending sale of non-core Coflex/CoFix assets and OUS businesses to Companion Spine expected to close by year-end 2025.
- Launched CollagenX bovine collagen particulate for surgical wound closure; potential across entire biologics portfolio.

## SEC filing metadata
- accession: 0001493152-25-021538
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315225021538/0001493152-25-021538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315225021538/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021538
- JSON: https://secwatch.observer/filing/0001493152-25-021538.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.